Actual Persistence of Abatacept in Rheumatoid Arthritis: Results of the French-Ric Network - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Journal of Clinical Medicine Année : 2020

Actual Persistence of Abatacept in Rheumatoid Arthritis: Results of the French-Ric Network

(1, 2) , (3) , (4) , (5, 1) , (6) , (7) , (8) , , (9) , (10) , (11) , (12) , (13)
1
2
3
4
5
6
7
8
9
10
11
12
13

Résumé

Objectives: Data on abatacept (ABA) persistence in routine practice are limited. We aimed to study ABA persistence rates at 12 months, according to the date of initiation, and to analyze the factors associated with persistence at 12 months. Methods: We performed an observational, ambispective, multi-center study from January 2008 to July 2016, based on the French-RIC Network. We defined three groups of patients followed up for rheumatoid arthritis (RA), according to the date of initiation of ABA therapy: Group 1 (from 2007 to 31 July 2010: ABA indicated after anti-TNF failure); Group 2 (from 1 August 2010 to 31 March 2014: ABA indicated after conventional antirheumatic drugs failure); Group 3 (from 1 April 2014 to 1 July 2016: ABA available by the subcutaneous injection). Results: Among 517 patients who initiated ABA, drug persistence at 12 months was 68%. The only factor significantly associated with persistence rate at 12 months was C-reactive protein (CRP) < 10 mg/L at ABA initiation (odds ratio (OR) 0.6, 95% confidence interval 0.3-0.9; p = 0.0016). There was no significant difference in drug persistence according to date of initiation, the line of biological disease-modifying antirheumatic drugs (bDMARD) therapy or the route of administration. Conclusions: In routine practice, over time, ABA has come to be initiated earlier in the course of therapy for RA in France. Abatacept persistence is similar to that reported in the Orencia Rheumatoid Arthritis (ORA) registry, and does not differ according to the date of initiation. The only factor found to be associated with the persistence rate at 12 months was CRP < 10 mg /L at ABA initiation.

Dates et versions

hal-03606080 , version 1 (11-03-2022)

Identifiants

Citer

Jean-Hugues Salmon, Jean-Guillaume Letarouilly, Vincent Goeb, Lukshe Kanagaratnam, Pascal Coquerelle, et al.. Actual Persistence of Abatacept in Rheumatoid Arthritis: Results of the French-Ric Network. Journal of Clinical Medicine, 2020, 9 (5), ⟨10.3390/jcm9051528⟩. ⟨hal-03606080⟩
4 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook Twitter LinkedIn More